Xdemvy Sets a New Standard in Demodex Blepharitis Care with FDA Nod
XTalks
AUGUST 9, 2023
a leader in developing therapeutic solutions for common diseases with limited treatment alternatives, has secured approval from the US Food and Drug Administration (FDA) for its drug, Xdemvy (lotilaner ophthalmic solution) 0.25%. California-based Tarsus Pharmaceuticals Inc., What Is Demodex Blepharitis?
Let's personalize your content